Indeed, we have reported the first instance of low dose (250nM) AF treatment resulting in cellular senescence, as shown using senescence-associated β-galactosidase staining, in Cal51shAhR human breast cancer cells, both in the presence and absence of AhR knockdown. The gene discussed is AHR; the disease is breast cancer.